Aripiprazole: Profile on efficacy and safety

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 12, 2002, Pages 1773-1781

  Goodnick, Paul J ^a   Jerry, Jerry M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Aripiprazole; Bipolar disorder; Diabetes; EKG; Lipids; Mania; Prolactin; Schizophrenia

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR; GLUCOSE; HALOPERIDOL; HISTAMINE; HISTAMINE RECEPTOR; LIPID; LITHIUM; MUSCARINIC M1 RECEPTOR; OLANZAPINE; PARTIAL AGONIST; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN 1A ANTAGONIST; SEROTONIN 2A ANTAGONIST; SERTINDOLE; THIORIDAZINE; VALPROATE SEMISODIUM; ZIPRASIDONE;

AGITATION; AGRANULOCYTOSIS; AKATHISIA; ANXIETY; ARTICLE; BINDING AFFINITY; BIPOLAR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; LIMBIC SYSTEM; LIPID BLOOD LEVEL; META ANALYSIS; PROLACTIN BLOOD LEVEL; QT INTERVAL; SCHIZOPHRENIA; SEDATION; SOMNOLENCE; SYNCOPE; TARDIVE DYSKINESIA; TREMOR; VERTIGO; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRAIN; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS; DIGESTIVE SYSTEM; DYSKINESIA, DRUG-INDUCED; HUMANS; MENTAL DISORDERS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 0036922793     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.12.1773     Document Type: Article

References (13)

1. GOODNICK PJ: Ziprasidone: profile on safety. Expert Opin. Pharmacother. (2001) 2(10):1655-1662.
2. CITROME L, JOSIASSEN R, BARK N, BROWN KS, MALLIKAARJUN S, SALAZAR DE: Pharmacokinetics and safety of aripiprazole and concomitant mood stabilizers. American Psychiatric Association Annual Meeting. Philadelphia, PA, USA (2002): Abstract NR317.
3. YEUNG P, MCQUADE RD, CARSON WH, SAHA A, ALI MW, INGENITO G: Aripiprazole and risperidone versus placebo in schizophrenia. Eur. Psychiatry (2002) 17(Suppl. 1):102-103.
4. LIEBERMAN JA, CARSON WH, SAHA AR et al.: Meta-analysis of the efficacy of aripiprazole in schizophrenia. American Psychiatric Association Annual Meeting. Philadelphia, PA, USA (2002):Abstract NR353.
5. KUJAWA M, SAHA A, INGENITO GG, ALI M, LUO X, ARCHIBALD DG: Aripiprazole for long-term maintenance treatment of schizophrenia. American Psychiatric Association Annual Meeting. Philadelphia, PA, USA (2002):Abstract NR376.
6. PIGOTT TA, SAHA AR, ALI MW et al.: Aripiprazole versus placebo in the treatment of stable, chronic schizophrenia. American Psychiatric Association Annual Meeting. Philadelphia, PA, USA (2002):Abstract NR 351.
7. KECK PE, SAHA A, IWAMOTO T et al.: Aripiprazole versus placebo in acute mania. American Psychiatric Association Annual Meeting. Philadelphia, PA, USA (2002):Abstract NR314.
8. CASEY DE, SAHA A, ALI M, JODY D, KUJAWA M, STOCK E, INGENITO GG: Switching to aripiprazole monotherapy. American Psychiatric Association Annual Meeting. Philadelphia, PA, USA (2002):Abstract NR310.
9. MAGUIRE GA: Prolactin elevation with antipsychotic medication: mechanism of action and clinical consequences. J. Clin. Psychiatry (2002) 63(Suppl. 4):56-62.
10. CARSON WH, STOCK E, SAHA AR, ALI MW, MCQUADE RD, KUJAWA MJ, INGENITO G: Safety and tolerability meta-analysis in schizophrenia. Eur. Psychiatry (2002) 17(Suppl. 1):106.
11. JODY D, SAHA A, IWAMOTO T et al.: Meta-analysis of weight effects with aripiprazole. American Psychiatric Association Annual Meeting. Philadelphia, PA, USA (2002):Abstract NR367.
12. c Interval. Expert Opin. Pharmacother. (2002) 3(5):479-498.
13. STOCK E, SAHA A, BRUNELL R, ARCHIBALD DG, IWAMOTOT, MCQUADE RD: Meta-analysis of cardiac safety with aripiprazole. American Psychiatric Association Annual Meeting. Philadelphia, PA, USA (2002):Abstract NR364.